Andrea Tan
Stock Analyst at Goldman Sachs
(1.97)
# 3,111
Out of 5,150 analysts
53
Total ratings
39.02%
Success rate
-5.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrea Tan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $206 → $327 | $265.00 | +23.40% | 2 | Feb 2, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Neutral | $50 → $85 | $65.10 | +30.57% | 3 | Jan 7, 2026 | |
| INSM Insmed | Maintains: Buy | $258 → $225 | $149.88 | +50.12% | 15 | Dec 18, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $16 → $8 | $4.26 | +87.79% | 7 | May 12, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Neutral | $46 → $51 | $76.20 | -33.07% | 4 | May 5, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $39 → $27 | $12.87 | +109.79% | 6 | Mar 25, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Neutral | $23 → $6 | $5.76 | +4.17% | 5 | Jul 1, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Sell | $3 → $2 | $4.77 | -58.07% | 3 | Jun 5, 2024 | |
| KOD Kodiak Sciences | Reinstates: Sell | $2 | $26.84 | -92.55% | 1 | Dec 11, 2023 | |
| ABCL AbCellera Biologics | Maintains: Buy | $27 → $24 | $3.63 | +561.16% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $4 | $1.45 | +175.86% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $375 | $434.80 | -13.75% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $80 | $15.05 | +431.56% | 2 | May 24, 2022 |
Krystal Biotech
Feb 2, 2026
Maintains: Buy
Price Target: $206 → $327
Current: $265.00
Upside: +23.40%
Arrowhead Pharmaceuticals
Jan 7, 2026
Maintains: Neutral
Price Target: $50 → $85
Current: $65.10
Upside: +30.57%
Insmed
Dec 18, 2025
Maintains: Buy
Price Target: $258 → $225
Current: $149.88
Upside: +50.12%
Iovance Biotherapeutics
May 12, 2025
Maintains: Buy
Price Target: $16 → $8
Current: $4.26
Upside: +87.79%
Tarsus Pharmaceuticals
May 5, 2025
Maintains: Neutral
Price Target: $46 → $51
Current: $76.20
Upside: -33.07%
Day One Biopharmaceuticals
Mar 25, 2025
Maintains: Buy
Price Target: $39 → $27
Current: $12.87
Upside: +109.79%
Sagimet Biosciences
Jul 1, 2024
Maintains: Neutral
Price Target: $23 → $6
Current: $5.76
Upside: +4.17%
Relmada Therapeutics
Jun 5, 2024
Downgrades: Sell
Price Target: $3 → $2
Current: $4.77
Upside: -58.07%
Kodiak Sciences
Dec 11, 2023
Reinstates: Sell
Price Target: $2
Current: $26.84
Upside: -92.55%
AbCellera Biologics
Aug 4, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $3.63
Upside: +561.16%
Jan 9, 2023
Maintains: Sell
Price Target: $10 → $4
Current: $1.45
Upside: +175.86%
Dec 20, 2022
Maintains: Buy
Price Target: $178 → $375
Current: $434.80
Upside: -13.75%
May 24, 2022
Maintains: Neutral
Price Target: $120 → $80
Current: $15.05
Upside: +431.56%